Albanian
Shqip
Arabic
العربية
Belarusian
Беларуская
Bengali
বাংলা
Bulgarian
Български
Cambodian
ខ្មែរ
Croatian
Hrvatski
Czech
Český
English
English
Esperanto
Esperanto
Filipino
Filipino
French
Français
German
Deutsch
Greek
Ελληνικά
Hausa
Hausa
Hebrew
עברית
Hungarian
Magyar
Hindi
हिन्दी
Indonesian
Bahasa Indonesia
Italian
Italiano
Japanese
日本語
Korean
한국어
Lao
ລາວ
Malay
Bahasa Melayu
Mongolian
Монгол
Myanmar
မြန်မာဘာသာ
Nepali
नेपाली
Persian
فارسی
Polish
Polski
Portuguese
Português
Pashto
پښتو
Romanian
Română
Russian
Русский
Serbian
Српски
Sinhalese
සිංහල
Spanish
Español
Swahili
Kiswahili
Tamil
தமிழ்
Thai
ไทย
Turkish
Türkçe
Ukrainian
Українська
Urdu
اردو
Vietnamese
Tiếng Việt
By continuing to browse our site you agree to our use of cookies, revised Privacy Policy and Terms of Use. You can change your cookie settings through your browser.
I agree
Search Trends
CHOOSE YOUR LANGUAGE
DOWNLOAD OUR APP
Copyright © 2026 CGTN.
京ICP备20000184号
京公网安备 11010502050052号
互联网新闻信息许可证10120180008
Disinformation report hotline: 010-85061466
"Both the UK and China are a great match in their shared focus on science and innovation," said Pascal Soriot, CEO of AstraZeneca, on Friday during the UK-China Business Forum in Beijing. He highlighted China's growing role as a key contributor to biopharmaceutical innovation and noted that UK Prime Minister Keir Starmer's visit to China is a strong signal of global collaboration. Just a day earlier, AstraZeneca announced a 100-billion-yuan ($15 billion) investment in China by 2030 to expand research and development and pharmaceutical manufacturing.